Clinical Trials Logo

Apathy clinical trials

View clinical trials related to Apathy.

Filter by:

NCT ID: NCT00548652 Completed - Obesity Clinical Trials

Role of Apathy in the Effectiveness of Weight Loss Interventions

Start date: August 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether treating apathy with methylphenidate or medical Crisis counselling will increase adherence to weight loss programs thereby increasing their effectiveness

NCT ID: NCT00495820 Completed - Dementia Clinical Trials

Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study

Start date: August 2007
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine the efficacy of methylphenidate over placebo in treating apathy in patients with Alzheimer's dementia. Apathy is one of the earliest and most profound disturbances that occur in Alzheimer's dementia (AD). Hypotheses: 1. Methylphenidate (MPH) will improve apathy significantly more than placebo in AD. 2. Successful treatment of apathy will improve Instrumental Activities of Daily Living (IADLs), and caregiver burden.

NCT ID: NCT00456820 Completed - Depression Clinical Trials

Wellbutrin XL Effects on SSRIs Induced Changes

Start date: July 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to find out differences in activation of mood regulating areas of the brain in response to negative and positive pictures, before and after 6 weeks of additional Wellbutrin XL treatment. Participants should have been treated for depression with an SSRI medication (e.g., Prozac, Zoloft, Paxil, Celexa or Lexapro) and have decreased depression symptoms but also be experiencing side effects of medications such as sexual side effects and feelings of apathy (indifference, lack of interest) and lack of full emotional response. We will first take a brain scan to measure activity in different parts of the brain, while subjects are seeing pictures, using Magnetic Resonance Imaging (MRI) scan. Then we will add Wellbutrin XL - another well-known antidepressant that acts by increasing the chemical dopamine in the brain, to subjects' treatment. Wellbutrin addition is useful in decreasing the sexual side effects of SSRIs. After treatment with Wellbutrin XL for 6 weeks subjects will have a second MRI scan with picture rating.